

# Vaccines and Global Health: The Week in Review 08 March 2025 :: Issue 789 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <a href="https://centerforvaccineethicsandpolicy.net">https://centerforvaccineethicsandpolicy.net</a>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

**Request email delivery of the pdf:** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <u>david.r.curry@centerforvaccineethicsandpolicy.org</u>.

**Support this knowledge-sharing service:** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: <u>Journal Watch</u>
- :: Pre-Print Servers
- :: Think Tanks
- :: Public Consultations/Call for Inputs/Call for Papers

## Milestones, Perspectives

:::::::

#### **Measles**

<u>Measles outbreaks in the Americas: PAHO calls for strengthened vaccination and surveillance</u>

Washington, D.C., 3 March 2025 (PAHO) – **The Pan American Health Organization (PAHO) has issued an <u>epidemiological alert</u> due to an increase in measles cases in several countries in <b>the Americas**. As of epidemiological week 8 of 2025 (21 February 2025), 268 measles cases, including one death, have been confirmed in Argentina, Canada, Mexico, and the United States. This represents a significant increase compared to the same period in 2024, when 60 cases were reported during the first eight weeks of the year.

Although the <u>region was reverified as measles-free in 2024</u>, measles remains a threat due to its continued circulation in other regions of the world, which increases the risk of importation through travelers, and the existence of unimmunized population groups that continue to be vulnerable. Of the 268 confirmed cases in 2025, 69% were in persons older than 5 years of age.

Last year, 17,887 suspected cases of measles were reported in the region, of which 464 were confirmed, with a notable proportion of these in adolescents and young adults. Notably, 63% of confirmed cases in 2024 had not been vaccinated, highlighting gaps in immunization coverage.

PAHO urgently calls on the countries and territories of the Americas to intensify their vaccination and epidemiological surveillance efforts, as well as to strengthen their rapid response capacity to contain and control outbreaks. Recommendations include intensifying vaccination campaigns, especially in high-risk areas, and improving surveillance to detect suspected cases of the disease in a timely manner.

It is also recommended that vaccination coverage with two doses of MMR (measles, rubella and mumps) vaccine be maintained above 95%, reaching all populations, with particular emphasis on children and young adults, who constitute a significant portion of the cases...

......

mPox - PHEIC

**IPPS - International Pandemic Preparedness Secretariat** [to 08 Mar 2025]

https://ippsecretariat.org/news/

News

Mpox remains a public health emergency: A status update

March 1, 2025 [Excerpts]

... Vaccines

It is encouraging to see an increase in vaccine dose delivery. However, significant challenges persist in the implementation of vaccination programmes. As reported by Africa CDC, to address this, the DRC has started a promising new vaccination strategy in Kinshasa, vaccinating 24,000 people within just four days of its initiation, with ambitious plans to reach 3.5 million. Vaccine supply will need to match this accelerated pace of administration. There also continues to be a lack of vaccine efficacy data

related to vulnerable populations, particularly pregnant women and young children who face heightened risk of severe complications. It is therefore encouraging to see the <a href="PregInPoxVac">PregInPoxVac</a> trial (NCT0684487 & NCT06844500) scheduled to commence in the first quarter of 2025, which aims to assess the safety and immunogenicity of the MVA-BN vaccine in pregnant and breastfeeding women, and infants under two years of age.

Conclusion

As we enter the next phase of response, there are still gaps that must be urgently addressed through sustained investment, accelerated research, and enhanced coordination between global health agencies, governments, and affected communities. The recent cuts in overseas development assistance (ODA) could significantly hamper the response as observed already with disruptions of sample transportation and surveillance, further underscoring the need for a more diversified and sustainable funding ecosystem. The coming months will require continued vigilance and a renewed commitment to ensuring that the tools needed to combat mpox reach those who need them most.

:::::::

#### Polio - PHEIC

#### Polio this week - 05 March 2025

#### Headlines

:: Humanitarian access improves quality of polio vaccination campaign in the Gaza Strip. Campaign reaches more than 630,000 children. More

;; Polio Oversight Board and high-level delegation visit Nigeria, as outbreak response intensifies. During visit, government, traditional leaders and partners renewed commitment to overcome remaining challenges to end polio in the country. More..

## Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: three WPV1 cases and 28 WPV1-positive environmental samples
- Algeria: two cVDPV2-positive environmental samples
- Cameroon: one cVDPV2 case and one cVDPV2-positive environmental sample
- Chad: four cVDPV2 cases and 3 cVDPV2-positive environmental samples
- Djibouti: one cVDPV2 case and two cVDPV2-positive environmental samples
- Guinea: one cVDPV2-positive environmental sample
- Nigeria: seven cVDPV2 cases

:::::::

#### **Featured Journal Content**

#### Science

6 Mar 2025, Vol 387, Issue 6738 Letter

#### Prepare now for a potential H5N1 pandemic

<u>Jesse L. Goodman</u>, <u>Norman W. Baylor</u>, <u>Rebecca Katz</u>, <u>Lawrence O. Gostin</u>, <u>Rick A. Bright</u>, <u>Nicole Lurie</u>, and <u>Bruce G. GellinAuthors Info & Affiliations</u>

[Excerpts]
The H5N1 vi

The H5N1 virus has crossed species and adapted to mammalian hosts, including dairy cattle, causing widespread exposure and sporadic human illness ( $\underline{I}$ ). Although most cases have been mild, H5N1 can cause severe disease ( $\underline{I}$ ). Given H5N1's potential to spread, urgent action is needed to address pandemic preparedness gaps.

Rapid influenza vaccine availability is highly constrained by currently approved technologies, such as protein-based vaccines (3, 4). Vaccine availability is also slowed by the time required to conduct immunogenicity and efficacy assessments and lot release and potency assays (5). Furthermore, many regulatory agencies lack the resources and capacity needed to quickly but robustly evaluate pandemic vaccines (5). To streamline vaccine development, assessment, production, and access, industry, governments, and regulators should enhance collaboration on new technologies, such as mRNA-based vaccines and vaccines using novel antigens; align regulatory pathways and requirements; and modernize immunogenicity assessment and lot release tools. To ensure equitable access, a global access framework should be established, including an entity that can provide financing and advanced vaccine purchases for low- and middle-income countries.

**Immunization programs are complex and demand advance planning**...Global, federal, state, and local authorities need to clearly understand their responsibilities and the circumstances under which plans activate. Consideration of societal and economic risks from both a pandemic and potential mitigations should be integrated into decision-making. Proactive analysis is also required to prepare for impacts on supply chains for vaccines and source materials as well as effects on health care and other sectors.

To effectively address these gaps, pandemic preparedness initiatives should be urgently resourced and implemented  $(\underline{6})$ .

**First, an effort to develop rapidly scalable pandemic influenza vaccines** [building on models such as Operation Warp Speed (7)] should engage industry, governments, regulators, and the scientific community, with equitable access supported by a funded global framework. Such an initiative would, ideally, also include development of and access to improved therapeutics, diagnostics, personal protective equipment, and other needed medical countermeasures.

**Second, a comprehensive outreach and communications program,** supported by behavioral science, should work to better understand and respond to concerns about vaccines and rebuild trust in public health.

**Finally, pandemic response plans should undergo transparent in-depth testing,** during which countries should share plans and playbooks and form global collaborations that incorporate different disease scenarios and immunization strategies.

Similar initiatives should address ongoing agricultural outbreaks (8).

Ennancing readiness	now can save lives	and reduce s	societal and econ	nomic disruption if	H2M1 of
another outbreak bec	comes a pandemic.				

::::::::

#### **Featured Journal Content**

## **Bull World Health Organization**

2025 Mar 1; 103(3): 226–228. Published online 2025 Jan 20.

Proposal for a fourth indicator on vaccine uptake in the joint external evaluation tool

Lawrence R Stanberry, Tariro Makadzange, Wilmot G James, Janan J Dietrich, Peter J Hotez, Shabir A Madhi, Susan L Rosenthal, Martin Veller, Natalia Pasternak Taschner, James W Le Duc, Youngmee Jee, Anthony L Cunningham, Margie Danchin, Julie Leask

doi: 10.2471/BLT.24.292086 PMCID: PMC11865845

[Excerpt]

## **New immunization uptake indicator**

...We suggest that stakeholders consider the adoption of a fourth immunization indicator that would evaluate countries' capacity for measuring the drivers of routine immunization uptake and ability to use the data to inform interventions to improve uptake ( $\underline{Box\ 1}$ ). This new indicator would be directly related to the first two indicators and why they may not be met: (i) measles-containing vaccine, dose one coverage at 12 months; and (ii) national vaccine access and delivery. As such, the new fourth indicator would work to provide data to formulate responses to gaps identified in the first and second indicators through understanding the social and behavioural drivers underpinning low vaccine uptake. The indicator would also identify barriers to service delivery and other factors that affect coverage to guide programme planning and strategies to improve uptake. The promotion of the new indicator would highlight the need for countries to allocate funding to build the capacity to undertake activities to understand the social and behavioural drivers ( $\underline{Table\ 1}$ ). Two existing programmes support countries in the development of the infrastructure, strategies, trained personnel and operations needed to implement the work required by the indicator – the Global Health Security Agenda<sup>10</sup> action package on immunization and the WHO/UNICEF Technet-21 programme.  $\underline{I}$ 

Box 1. Components of a potential fourth indicator for the joint external evaluation tool.

Drivers of vaccine uptake

- Mechanisms in place to collect data on the behavioural and social drivers of vaccination.
- Evidence of routine data gathering and other insights from relevant stakeholders to inform programme planning.
- Evidence of programme planning to support optimization of person-centred immunization service delivery and strategies to sustain and increase confidence in vaccination.
- Evidence of implementation and evaluation of strategies to increase coverage.

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO

::::::

.....

- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

### WHO & Regional Offices [to 08 Mar 2025]

https://www.who.int/news

Selected News/Announcements/Statements

8 March 2025 News release

Many pregnancy-related complications going undetected and untreated - WHO

6 March 2025 News release

WHO announces new collaborating centre on AI for health governance

::::::

## **WHO Regional Offices**

Selected Press Releases, Announcements

#### **WHO African Region AFRO**

:: 03 March 2025

Sustaining efforts to end mpox outbreak in Burundi

### **WHO Region of the Americas PAHO**

:: 5 Mar 2025

<u>PAHO Director Underscores the Need to Address Public Health Challenges in Latin America</u> and the Caribbean and Proposes Innovative Solutions

Cuernavaca, Mexico – March 5, 2025 (PAHO) – Within the framework of the inauguration of the Mexican National Institute the Public Health's (INSP) 20th Public Health Research Congress 2025, the Director of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa, highlighted the challenges facing public health in Latin America and the...

:: 3 Mar 2025

<u>Measles outbreaks in the Americas: PAHO calls for strengthened vaccination and surveillance</u>

Washington, D.C., 3 March 2025 (PAHO) – The Pan American Health Organization (PAHO) has issued an epidemiological alert due to an increase in measles cases in several countries in the Americas. As of epidemiological week 8 of 2025 (21 February 2025), 268 measles cases, including one death, have been confirmed in Argentina, Canada, Mexico, and the...

#### **WHO South-East Asia Region SEARO**

No new digest content identified.

## **WHO European Region EURO**

:: 4 March 2025 News release

New data dashboard visualizes progress towards vaccine-preventable disease control and immunization equity in Europe

## WHO Eastern Mediterranean Region EMRO

No new digest content identified.

### **WHO Western Pacific Region**

:: 3 March 2025 News release

WHO calls for investment in health-care infection and prevention control

::::::

## **WHO - Emergency situation reports**

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

No new digest content identified.

::::::

## **Disease Outbreak News (DONs)**

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

## 8 March 2025 | Sudan virus disease - Uganda

## 3 March 2025 | Cluster of community deaths in Basankusu, Equateur- Democratic Republic of the Congo

Situation at a glance

On 9 February 2025, officials in the Democratic Republic of the Congo reported to regional health authorities a cluster of 24 unexplained community deaths in a single village in Ekoto health area, Basankusu health zone, Equateur province. As of 25 February, a total of 53 deaths have been reported, with the last death occurring on 22 February. Deaths have occurred in all age groups, but adolescents and young adults, particularly males, appeared to be disproportionately affected in the initial cluster reported. Disease progression appeared to be fast, with a median time from onset of symptoms to death of one day. Given the rapid decline in the incidence of reported deaths, their geographic clustering, the age profile of deaths and the rapid disease progression in the initial cluster, working hypotheses include chemical poisoning or a rapid onset bacterial meningitis cluster, on a background of malaria and other infectious illnesses endemic in the region. The definitive cause of illness remains undetermined...

::::::

#### **Weekly Epidemiological Record**

Vol. 100, No. 09, pp. 61-74 28 February 2025

https://www.who.int/publications/journals/weekly-epidemiological-record

PDF: https://iris.who.int/bitstream/handle/10665/380670/WER10009-eng-fre.pdf

:: Report of the 4th joint meeting of the WHO Global Advisory Committee on Vaccine Safety and the Advisory Committee on Safety of Medicinal Products, 12-14 November 2024

::::::

#### **New WHO Publications**

https://www.who.int/publications

Selected

7 March 2025

Report of the 4th joint meeting of the WHO Global Advisory Committee on Vaccine Safety and the...

7 March 2025

## A global review of value-based care: theory, practice and lessons learned

Overview

Health systems globally are exploring avenues for maximizing value and transitioning out of a volume-based approach to health service provision and financing. This document is a global review of efforts being undertaken in value-based health care and the emerging paradigm for enhancing health systems accountability, efficiency and effectiveness.

6 March 2025

## Syndromic screening for infection prevention and control measures during public health emergencies

**Overview** 

This technical note describes a simplified screening approach for health-care settings to engage in the early detection and safe placement of patients with syndromes of suspected infections that are known to rapidly transmit as health care-associated infections. This includes active and passive screening tools that may facilitate systematic screening of all patients – both inpatients and outpatients – for signs and symptoms of suspected infectious rash, infectious diarrhoea or acute respiratory infection. Also included is contextual information relevant to implementing syndromic screening for IPC measures in the context of public health emergencies and advice for linking syndromic screening with emergency surveillance systems.

5 March 2025

The case for investment and action in infection prevention and control

4 March 2025

WHO Technical Advisory Group on the responsible use of the life sciences and dual-use research: report...

Overview

The World Health Organization (WHO) Technical Advisory Group on the Responsible Use of the Life Sciences and Dual-Use Research (TAG-RULS DUR) was established to provide independent advice to WHO on the monitoring and mitigation of biorisks, the advances in the life sciences and related technologies, the governance of dual-use research and the responsible use of the life sciences. This report summarizes the meeting that was virtually held on 30 October 2024. Over the course of the meeting, participants discussed and provided feedback on activities to operationalize the framework and delivered updates on activities of the TAG-RULS DUR's four working groups.

4 March 2025

Accelerating the development of priority formulations for antibiotic use in children: target product...

::::::

**USA - HHS, FDA, CDC+** 

#### Editor's Note:

We employ bolded red text below to identify observations we assess might be useful to readers.

#### **HHS**

News

<u>DOJ, HHS, ED, and GSA Announce Initial Cancelation of Grants and Contracts to Columbia University Worth \$400 Million</u>

March 7, 2025 Press Release

#### Measles Outbreak is Call to Action for All of Us

March 3, 2025 *Op-Ed - Robert F. Kennedy, Jr., HHS Secretary MMR vaccine is crucial to avoiding potentially deadly disease* 

As the Secretary of the U.S. Department of Health and Human Services, I am deeply concerned about the <u>recent measles outbreak</u>. This situation has escalated rapidly, with the Texas Department of

State Health Services (DSHS) reporting 146 confirmed cases since late January 2025, primarily in the South Plains region. Tragically, this outbreak has claimed the life of a school-aged child, the first measles-related fatality in the United States in over a decade.

Vaccines not only protect individual children from measles, but also contribute to community immunity, protecting those who are unable to be vaccinated due to medical reasons...

#### **FDA**

Press Announcements

FDA Roundup: March 7, 2025

#### **FDA VRBPAC**

Advisory Committee Calendar

The Advisory Committee calendar does not list any future scheduled meetings of any FDA advisory committee, including VRBPAC.

**CDC/ACIP [U.S.]** [to 08 Mar 2025]

http://www.cdc.gov/media/index.html

Latest News

No new digest content identified.

**ACIP Meetings** [to 08 Mar 2025]

Next ACIP Meeting

**ACIP Meeting February 26-28, 2025 Postponed** 

"The ACIP meeting will be postponed to accommodate public comment in advance of the meeting. The ACIP workgroups met as scheduled this month and will present at the upcoming ACIP meeting." Agenda for February 26-28

[Agenda appears stable from earlier agenda versions]

#### **National Vaccine Program**

https://www.hhs.gov/vaccines/about/index.html

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

#### **MMWR Weekly**

https://www.cdc.gov/mmwr/index2024.html

The MMWR has resumed publication with the posting of these editions:

March 6, 2025 / No. 7 [selected content]

PDF of this issue

- Idiopathic Pulmonary Fibrosis Mortality by Industry and Occupation United States, 2020–2022
- Notes From the Field: Enhanced Identification of Tobacco Use Among Adult Medicaid Members King County, Washington, 2016–2023
- Notes from the Field: Tobacco Product Use Among Adults United States, 2017–2023
- *Notes from the Field*: Detection of Vaccine-Derived Poliovirus Type 2 in Wastewater Five European Countries, September–December 2024
- QuickStats: Percentage of Adults Aged ≥18 Years with Chronic Pain in the Past 3 Months, by Sex and Urbanization Level United States, 2023

## February 27, 2025 / No. 6 [selected content]

PDF of this issue

 Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025

- <u>Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness Four Vaccine Effectiveness Networks, United States, October 2024–February 2025</u>
- Reports of Encephalopathy Among Children with Influenza-Associated Mortality United States, 2010–11 Through 2024–25 Influenza Seasons
- <u>Trends in Cervical Precancers Identified Through Population-Based Surveillance Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022</u>
- Avian Influenza A(H5) Subtype in Wastewater Oregon, September 15, 2021–July 11, 2024
- QuickStats: Percentage Distribution of Deaths Attributed to Excessive Cold or Hypothermia, by Month — United States, 2023

## February 20, 2025 / No. 5 [selected content]

#### PDF of this issue

- Dengue Outbreak and Response Puerto Rico, 2024
- <u>Highly Pathogenic Avian Influenza A(H5N1) Virus Infection of Indoor Domestic Cats Within Dairy</u> Industry Worker Households — Michigan, May 2024
- Notes from the Field: Genomic and Wastewater Surveillance Data to Guide a Hepatitis A Outbreak Response Los Angeles County, March 2024—June 2024
- Notes from the Field: Elevated Atmospheric Lead Levels During the Los Angeles Urban Fires California, January 2025

## February 13, 2025 / No. 4 [selected content]

#### PDF of this issue

- First Clade Ib Monkeypox Virus Infection Reported in the Americas California, November 2024
- Notes from the Field: Seroprevalence of Highly Pathogenic Avian Influenza A(H5) Virus Infections Among Bovine Veterinary Practitioners United States, September 2024

## **February 6, 2025 / No. 3** [selected content]

### PDF of this issue

- Notes from the Field: Serum Concentrations of Perfluoroalkyl and Polyfluoroalkyl Substances
  Among First Responders to the Maui Wildfires Hawaii, September 2023
- Notes from the Field: Emergency Department Use During the Los Angeles County Wildfires, January 2025

	:		

#### **Europe**

## **European Medicines Agency [EMA]**

https://www.ema.europa.eu/en/news

News & Press Releases

## New clinical trial map launched in the EU

Patients can locate trials for potential enrolment in their area 3 March 2025

## **European Centre for Disease Prevention and Control**

https://www.ecdc.europa.eu/en

News/Updates/Reports/Publications [Selected]

News

<u>Joint EFSA-ECDC EU report: Bacteria resistant to key antimicrobials still routinely found in</u> humans and animals

5 Mar 2025

## Joint ECDC-WHO/Europe mpox surveillance bulletin

3 Mar 2025

Surveillance and monitoring

## Communicable disease threats report, 1 - 7 March 2025, week 10

7 Mar 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 1 - 7 March 2025 and includes updates on cholera associated with holy well water from Ethiopia, chikungunya, Avian flu detected in cats, SARS-CoV-2 variant classification, an overview of respiratory virus epidemiology in the EU/EEA, measles, Ebola, and MERS.

::::::

Africa CDC [to 08 Mar 2025]

https://africacdc.org/

Press Releases, Statements [Selected]

## Renewed Commitment to Strengthen Public Health Surveillance and Address Disease Outbreaks in Africa

Addis Ababa, March 06, 2025 – The Africa Centres for Disease Control and Prevention (Africa CDC) and Illumina (NASDAQ: ILMN), a global leader in sequencing technology, strengthen their collaboration to advance the **Africa Pathogen Genomics Initiative (Africa PGI)**.

The renewed commitment builds on existing efforts over the last 4 years to address COVID-19 and other infectious disease outbreaks, as well as tackle emerging public health threats and endemic diseases like tuberculosis, malaria, and cholera.

Together, both organizations are focused on broadening access to next-generation sequencing (NGS) tools and expertise and enhancing public health surveillance and laboratory networks across Africa.

"Africa CDC is pleased to continue its collaboration with Illumina and other partners to enhance Africa's capacity to detect and respond to emerging health threats. Genomics is transforming disease surveillance, and this collaboration will help integrate next-generation sequencing into routine public health systems. Our goal remains clear — by the end of 2025, all 55 National Public Health Institutes (NPHIs) will have operational NGS capacity to better protect Africa's health." said H.E. Dr. Jean Kaseya, Director-General, Africa CDC.

Since the inception of this collaboration in March 2021, Illumina has provided significant contributions, including next-generation sequencing (NGS) platforms, reagents, and training support. As a part of this association, additional sequencing instruments and reagents will be provided to around 25 countries...

::::::

#### China CDC+

http://www.chinacdc.cn/en/

**National Health Commission of the People's Republic of China** [to 08 Mar 2025]

http://en.nhc.gov.cn/

News

No new digest content identified.

National Medical Products Administration – PRC [to 08 Mar 2025]

http://english.nmpa.gov.cn/

News

No new digest content identified.

#### **China CDC**

## CCDC Weekly Reports: Current Volume (7) 2025-03-07 / No. 10 INTERNATIONAL WOMEN'S DAY

PDF of this issue

- :: Foreword: Towards Equity in Women's Health: Bridging Promises, Action, and Progress [Excerpt]
  - ... Additionally, women's health equity represents not merely a healthcare concern but also an economic and workforce imperative. To accelerate progress, six strategic priorities warrant immediate attention. First, enhancing comprehensive data collection systems to capture the nuanced needs of diverse female populations is essential. Second, expanding support for basic science and clinical research focused on women-specific conditions is critical to address persistent gaps in evidence-based care. Third, developing sex-based healthcare delivery systems will ensure more tailored and effective services across the lifespan. Fourth, implementing accessible solutions can effectively bridge geographic and socioeconomic barriers to care. Fifth, directing substantial resources into women's health fields will create sustainable infrastructure to support these comprehensive efforts. Finally, ensuring workplace accommodations for pregnant, postpartum, and menopausal women is vital to promote long-term well-being and productivity. By prioritizing these strategic actions, China can establish global leadership in addressing the women's health gap.
- :: Preplanned Studies: Cervical Cancer Screening Rates Among Chinese Women China, 2023–2024
- :: <u>Preplanned Studies: Association Between High-Risk Human Papillomavirus Infection and Cervical Cytology in Health Check-Up Women 23 PLADs, China, 2023</u>

::::::

## Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

## **Organization Announcements**

**Paul G. Allen Frontiers Group** [to 08 Mar 2025]

https://alleninstitute.org/news-press/

News

No new digest content identified.

**BMGF - Gates Foundation** [to 08 Mar 2025]

https://www.gatesfoundation.org/ideas/media-center

Press Releases & Statements No new digest content identified.

### https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications No new digest content identified.

## **CARB-X** [to 08 Mar 2025]

https://carb-x.org/

News

No new digest content identified.

## **Chan Zuckerberg Initiative** [to 08 Mar 2025]

https://chanzuckerberg.com/newsroom/

Newsroom

No new digest content identified.

## **CEPI – Coalition for Epidemic Preparedness Innovations** [to 08 Mar 2025]

http://cepi.net/ CEPI News, Blog

News

#### The world should prepare now for a potential H5N1 flu pandemic, experts warn

The rapid spread and mutation of a deadly bird flu virus in the United States warrants urgent global action, says experts

6 Mar 2025

## CIOMS - COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 08

Mar 2025]

https://cioms.ch/

News; Publications; Events No new digest content identified.

#### **DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 08 Mar 2025]

https://www.darpa.mil/news

News

No new digest content identified.

### **DNDI – Drugs for Neglected Diseases initiative** [to 08 Mar 2025]

https://dndi.org/press/press-releases/

Press Releases

No new digest content identified.

#### **Duke Global Health Innovation Center** [to 08 Mar 2025]

https://dukeghic.org/

News

<u>Issue 9: 6 March 2025 | Mpox: Transparency and Accountability for the Global Response</u> March 6, 2025

**EDCTP** [to 08 Mar 2025]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

05 March 2025

First preschool-aged child receives arpraziquantel for schistosomiasis treatment

**Emory Vaccine Center** [to 08 Mar 2025]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

**European Vaccine Initiative** [to 08 Mar 2025]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified.

Fondation Merieux [to 08 Mar 2025]

http://www.fondation-merieux.org/ News, Events No new digest content identified.

**Gavi** [to 08 Mar 2025] https://www.gavi.org/ Press Releases 7 March 2025

## Uganda Minister of Health receives and flags off malaria vaccines to 105 districts

Kajjansi, 7 March 2025 – The Minister of Health, Hon. Dr Jane Ruth Aceng Ocero, has today officially flagged off the distribution of 2.278 million doses (out of a total quantity of 3.5 million doses) of malaria vaccines to 105 districts with high and moderate transmission across Uganda, marking a major milestone in the country's fight against malaria.

The vaccination will eventually be rolled out to the entire country. This initiative is made possible through the support of Gavi, the Vaccine Alliance, with co-financing from the Government of Uganda. The procurement and air freighting of the vaccines have been undertaken by UNICEF, ensuring timely delivery of a high-quality vaccine.

The malaria vaccine will be introduced into the routine immunisation schedule in April 2025, targeting children aged below two years. This will be the largest malaria vaccine introduction to date in terms of the number of districts and target population. The four-dose vaccine will be administered at 6, 7, 8 and 18 months, ensuring optimal protection from malaria during the most vulnerable stages of early childhood...

#### 7 March 2025

#### Statement on Global High-Level Summit in support of Gavi replenishment

Geneva/Brussels/Seattle, 7 March 2025 – Gavi, the Vaccine Alliance along with co-hosts the European Union and the Gates Foundation today announce that the Global Summit: Health & Prosperity through Immunization, in support of Gavi's next five-year strategic period, **will be held in Brussels on 25**June 2025.

The Summit, which will coincide with the European Council Meeting, was previously scheduled 19-20 March 2025. Today's decision to select a new date was taken collectively to ensure that this Summit is keenly focused on Gavi's core mission of protecting children and communities around the world and helping to protect our world from disease outbreaks.

7 March 2025

#### Canada pledges new support to Gavi

Canada makes pledge of CAD 675 million in new funding for Gavi, the Vaccine Alliance's next strategic period from 2026 to 2030

### **GE2P2 Global Foundation** [to 08 Mar 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review February 2025
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 21 Feb 2025

## <u>Expression of Concern :: U.S. Vaccine/Immunization Science & Policy: Interruption of Expert Advisory Committees & Public Comment Processes</u>

08 Mar 2025

**GHIT Fund** [to 08 Mar 2025]

https://www.ghitfund.org/newsroom/press

Press Releases

March 5, 2025

GHIT-backed Innovation Achieves Landmark: New Treatment Option for Schistosomiasis Reaches Preschool-Aged Children

Global Fund [to 08 Mar 2025]

https://www.theglobalfund.org/en/news/

News Releases

No new digest content identified.

## Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 08 Mar

2025]

https://www.glopid-r.org/news/

News

No new digest content identified.

#### **Hilleman Laboratories** [to 08 Mar 2025]

http://www.hilleman-labs.org/

News & Insights
No new digest content identified.

## **HHMI - Howard Hughes Medical Institute** [to 08 Mar 2025]

https://www.hhmi.org/news

Press Room

No new digest content identified.

## **Human Immunome Project [nee Human Vaccines Project]** [to 08 Mar 2025]

https://www.humanimmunomeproject.org/

News

No new digest content identified.

**IAVI** [to 08 Mar 2025]

https://www.iavi.org/

Press Releases, Features

**Features** 

#### Meet the women at the helm of IAVI's Lassa program

March 6, 2025

IAVI commemorates International Women's Day 2025.

In The News

## Second cluster reported in Uganda's Ebola Sudan outbreak

CIDRAP March 6, 2025

**INSERM** [to 08 Mar 2025]

https://www.inserm.fr/en/home/

Press Releases

No new digest content identified.

#### International Coalition of Medicines Regulatory Authorities [ICMRA]

http://www.icmra.info/drupal/en/news

Selected Statements, Press Releases, Research

No new digest content identified.

## ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 08 Mar 2025]

https://www.ich.org/

News/Pubs/Press Releases [Selective]

No new digest content identified.

**ICRC** [to 08 Mar 2025]

https://www.icrc.org/en/whats-new

Latest press releases and statements [Selected]

Article 06-03-2025

## **Strengthening Respect for IHL: Building on Commonalities with Islamic Law**

17-19 February 2025

The opening speech was given by Dr Gilles Carbonnier, ICRC Vice President, at the 3rd International Conference on IHL in light of Islamic Jurisprudence, at the College of Sharia Sciences, Muscat, Oman.

#### **IFFIm**

http://www.iffim.org/ Press Releases/Announcements No new digest content identified.

**IFRC** [to 08 Mar 2025]

http://media.ifrc.org/ifrc/news/press-releases/

Press Releases [Selected]

Statement: Without access to aid into Gaza Strip, people's lives are on a knife-edge once again

02/03/2025 | Press release

## **IPPS - International Pandemic Preparedness Secretariat** [to 08 Mar 2025]

https://ippsecretariat.org/news/

News

Mpox remains a public health emergency: A status update

March 1, 2025

## **Institut Pasteur** [to 08 Mar 2025]

https://www.pasteur.fr/en/press-area

Press Documents

Press Info 06.03.2025

## **How AI will make it easier to anticipate future pandemics**

In a *Nature* perspective paper, scientists across Africa, America, Asia, Australia, and Europe outline for the first...

Press Info 06.03.2025

Stand Up for Science: the Institut Pasteur is committed to defending science and supporting the solidarity movement towards the American scientific community

#### **ISC / International Science Council** [to 08 Mar 2025]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

blog

06 March 2025 - 6 min read

Opinion: Nurturing 'wild horses' in science is a universal goal

news

05 March 2025 - 8 min read

## <u>Call for members to the operational committees of the ISC Regional Focal Point for Latin</u> America and the Caribbean

## **International Union of Immunological Societies (IUIS)**

https://iuis.org/

News/Events [Selected]

## 19th International Congress of Immunology

Vienna, August 17-22, 2025.

**IVAC** [to 08 Mar 2025]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

No new digest content identified.

**IVI** [to 08 Mar 2025]

http://www.ivi.int/

IVI News & Announcements

No new digest content identified.

## **Johns Hopkins Center for Health Security** [to 08 Mar 2025]

https://centerforhealthsecurity.org/newsroom

Center News [Selected]

No new digest content identified.

## MSF/Médecins Sans Frontières [to 08 Mar 2025]

http://www.msf.org/

Latest [Selected Announcements]

Gaza-Israel war

"People in Gaza still need an immediate and massive scale-up of humanitarian supplies"

Voices from the Field 7 Mar 2025

South Sudan

#### Three vaccinations that are critical to women's health

Project Update 7 Mar 2025

Haiti

## In Haiti, escalating violence increases displacement and basic needs

Project Update 6 Mar 2025

## National Academy of Medicine - USA [to 08 Mar 2025]

https://nam.edu/programs/

News [Selected]

No new digest content identified.

https://www.nationalacademies.org/newsroom

News

No new digest content identified.

NIH [to 08 Mar 2025] http://www.nih.gov/ News Releases

NIH centralizes peer review to improve efficiency and strengthen integrity

March 6, 2025 — The proposed approach is expected to save more than \$65 million annually.

PATH [to 08 Mar 2025] https://www.path.org/media-center/ Newsroom [Selected] No new digest content identified.

**Sabin Vaccine Institute** [to 08 Mar 2025]

https://www.sabin.org/press/ Latest News & Press Releases No new digest content identified.

http://www.unaids.org/en News, Stories, Updates

Press Statement 06 March 2025

<u>UNAIDS calls for rights, equality and empowerment for all women and girls on International Women's Day</u>

Feature Story

<u>Impact of US funding freeze on the global AIDS response — Week of 3 March 2025 update</u> 04 March 2025

Eleven UNAIDS' Country Offices submitted new reports on the impact of the freeze of US foreign assistance on their country AIDS responses during the week of 24-28 February. As of 28 February, at least one status report had been received from 59 countries, including 79% of all PEPFAR-funded countries and an additional 15 countries that receive US support for their AIDS responses.

Last week, the U.S. Government issued termination letters for many agreements held by USAID. This decision is expected to significantly alter the situation reported by countries in the coming days. For example, in South Africa dozens of USAID implementing partners received termination letters on 26 February. These decisions will affect a large proportion of the 15,374 PEPFAR-funded staff working on the national HIV response in South Africa. Managers of critical programmes have said they have been given too little time to transition from U.S. funding to other sources of funding.

**UNICEF** [to 08 Mar 2025]

https://www.unicef.org/media/press-releases

Latest press releases, news notes and statements [Selected]

News note 07 March 2025

Fast Facts: 30 years of uneven progress for adolescent girls

NEW YORK, 7 March 2025 – Despite significant achievements in areas such as education over the last three decades, millions of adolescent girls across the world today are still out of school, ill-equipped for the future, facing gaps in life-saving health services, and at risk of harmful practices such as child marr...

Statement 06 March 2025

## Statement by UNICEF Executive Director Catherine Russell on global foreign aid reductions

NEW YORK, 5 March 2025 — "Announced and anticipated funding cuts will limit UNICEF's ability to reach millions of children in dire need. "These cuts by numerous donor countries follow two years of aid reductions at a time of unprecedented need. Millions of children are affected by conflict, need to be vaccinated against deadly diseases such as...

Press release 03 March 2025

## <u>UNICEF reaches 364,000 children daily in Goma with clean water and sanitation after</u> escalation in DR Congo conflict

GOMA, DR Congo, 3 March 2025 – UNICEF and its partners in the Democratic Republic of the Congo (DRC) are providing life-saving clean water supplies to 700,000 people a day – around 364,000 children – in the main eastern city of Goma after breaks in the water supply during fighting. The intense conflict at the end ...

Press release 03 March 2025

## With stoppage of humanitarian aid deliveries into the Gaza Strip, UNICEF warns of severe consequences for children and families in desperate need

NEW YORK / AMMAN, 3 March 2025 – UNICEF is warning that the stoppage of aid deliveries into the Gaza Strip will quickly lead to devastating consequences for children and families across Gaza who are struggling to survive. "The aid restrictions announced yesterday will severely compromise lifesaving operations for ...

**Unitaid** [to 08 Mar 2025]

https://unitaid.org/ Featured News News releases

<u>Medical oxygen a lifesaving investment: Landmark report launched by The Lancet Global</u> Health Commission

06 March 2025

#### **Vaccine Equity Cooperative [nee Initiative]** [to 08 Mar 2025]

https://vaccineequitycooperative.org/news/

News

No new digest content identified.

## Vaccination Acceptance & Demand Initiative [Sabin) [to 08 Mar 2025]

https://www.vaccineacceptance.org/

News

No new digest content identified.

## **Vaccine Confidence Project** [to 08 Mar 2025]

http://www.vaccineconfidence.org/

News, Research and Reports No new digest content identified.

## **Vaccine Education Center – Children's Hospital of Philadelphia** [to 08 Mar 2025]

http://www.chop.edu/centers-programs/vaccine-education-center

News

No new digest content identified.

## Wellcome Trust [to 08 Mar 2025]

https://wellcome.org/news/all News. Opinion, Reports No new digest content identified

## **The Wistar Institute** [to 08 Mar 2025]

https://www.wistar.org/news/press-releases

Press Releases

No new digest content identified.

#### World Bank [to 08 Mar 2025]

http://www.worldbank.org/en/news/all

All News [Selected]

No new digest content identified.

#### WFPHA: World Federation of Public Health Associations [to 08 Mar 2025]

https://www.wfpha.org/

Blog, Events

## Why Inclusion in Science Is Essential for Public Health Progress

Mar 5, 2025

Science and public health are at their best when they are inclusive. Diversity in research leads to better outcomes, more innovative solutions, and a deeper understanding of the...

#### World Medical Association [WMA] [to 08 Mar 2025]

https://www.wma.net/news-press/press-releases/

Press Releases

No new digest content identified.

## World Organisation for Animal Health [OIE] [to 08 Mar 2025]

https://www.oie.int/ Press Releases, Statements No new digest content identified.

::::::

https://alliancerm.org/press-releases/

Selected Press Releases

No new digest content identified.

**BIO** [to 08 Mar 2025]

https://www.bio.org/press-releases

Press Releases

No new digest announcements identified.

## **DCVMN – Developing Country Vaccine Manufacturers Network** [to 08 Mar 2025]

http://www.dcvmn.org/

News; Upcoming events

No new digest announcements identified.

### **ICBA – International Council of Biotechnology Associations** [to 08 Mar 2025]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

**IFPMA** [to 08 Mar 2025]

https://ifpma.org/

News, Statements [Selected]

No new digest announcements identified.

## **International Alliance of Patients' Organizations – IAPO** [to 08 Mar 2025]

https://www.iapo.org.uk/news

Press and media [Selected]

No new digest announcements identified.

#### **International Generic and Biosimilar Medicines Association [IGBA]**

https://www.igbamedicines.org/

News

No new digest announcements identified.

**PhRMA** [to 08 Mar 2025]

http://www.phrma.org/

Press Releases

No new digest announcements identified.

::::::

Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

**AstraZeneca** 

<u>Press Releases</u> - No new digest content identified.

#### **Bavarian Nordic**

Latest News

March 07, 2025

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

#### **Bharat Biotech**

<u>Press Releases</u> - No new digest announcements identified

#### **BioCubaFarma** – Cuba

Últimas Noticias

Identifican áreas de cooperación BioCubaFarma y Universidad de Artemisa

Lun, 03/03/2025 - 12:43

## **Biological E**

News - No new digest announcements identified

#### **BioNTech**

Press Releases - No new digest announcements identified

## Boehringer

Press Releases

## <u>Boehringer Ingelheim enhances biopharmaceutical contract manufacturing services in China</u>

Ingelheim, Germany, Tue, 04/03/2025 - 10:00

Boehringer Ingelheim's biopharmaceutical facility in Shanghai, China, meets the conditions to participate in a regulatory reform promoting segmented manufacturing of biological products by the local authorities. The reform, led by the Chinese medicine authority NMPA (National Medical Products Administration), aims at enhancing control, efficiency, and flexibility in the production process. As one of the few contract manufacturing organizations qualified for the pilot period, Boehringer Ingelheim BioXcellence™ is expanding its service portfolio in China, offering distinct service packages for different segments in biopharmaceutical production and enabling the sustainable global supply of medications to patients.

#### **CanSinoBIO**

<u>News</u> - Website not responding at inquiry

#### **CIGB**

<u>Latest News</u> - No new digest announcements identified.

#### CinnaGen

<u>Recent News</u> - No new digest announcements identified.

#### **Clover Biopharmaceuticals** – China

News - No new digest announcements identified.

#### Curevac

News - No new digest announcements identified.

#### **Gamaleya National Center/Sputnik**

<u>Latest News and Events</u> - No new digest announcements identified [Last: 09 Nov 2020] <u>https://sputnikvaccine.com/</u> - No new digest announcements identified [Last: 31 Aug 2022]

#### **GSK**

Press releases for media

06 March 2025

## GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults

- :: World-leading experts to focus on RSV, a significant public health challenge with an estimated 64 million people of all ages impacted every year1
- :: 17 abstracts to evaluate unmet medical need and approaches to RSV prevention in adults
- :: Results include immunogenicity and safety data for GSK's RSV vaccine

### **EuBiologics,** S Korea

News - No new digest announcements identified.

### IMBCAMS, China

Home - Website not responding at inquiry.

## JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

#### Merck

<u>News releases</u> - No new digest announcements identified

#### Moderna

<u>Press Releases</u> - No new digest announcements identified

#### Nanogen

News - No new digest announcements identified

#### **Novartis**

News - No new digest announcements identified.

#### **Novavax**

<u>Press Releases</u> - No new digest announcements identified

#### **Pfizer**

Recent Press Releases - No new digest announcements identified.

#### R-Pharm

https://rpharm-us.com/index.php

[No news or media page identified]

#### Sanofi Pasteur

Press Releases - No new digest announcements identified.

#### **Serum Institute**

News & Announcements - No new digest announcements identified.

#### Sinopharm/WIBPBIBP

News - No new digest announcements identified.

#### Sinovac

<u>Press Releases</u> - No new digest announcements identified.

#### **SK Biosciences**

<u>Press Releases</u> - No new digest announcements identified.

#### **Takeda**

<u>Newsroom</u> - No new digest announcements identified.

#### **Valneva**

<u>Press Releases</u> - No new digest announcements identified.

## **Vector State Research Centre of Viralogy and Biotechnology**

<u>Home</u> - [Website not responding [404 error]

## **WestVac Biopharma**

Media - No new digest announcements identified.

## Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

### Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

#### Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: <a href="mailto:david.r.curry@centerforvaccineethicsandpolicy.org">david.r.curry@centerforvaccineethicsandpolicy.org</a>

## **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 1 <a href="https://www.tandfonline.com/toc/uabr21/current">https://www.tandfonline.com/toc/uabr21/current</a> [Reviewed earlier]

#### **AMA Journal of Ethics**

March 2025 Volume 27, Number 3: E167-236

https://journalofethics.ama-assn.org/issue/regret-moral-psychology-surgical-professionalism

## Issue Theme: Regret in the Moral Psychology of Surgical Professionalism

Along a physician's training path to becoming a surgeon, there are few, if any, formal or structured opportunities to reflect upon regret experiences. But the influences regret can have in surgeons' practices is worth considering, given that some patients suffer poor outcomes despite surgeons' long-term training, sound decision-making, competent practice, best efforts, and good intentions. This theme issue investigates regret as an expression of a surgeon's moral psychological development and their deep internalization of their capacity to harm. This theme issue also considers how we should regard regret and its kindred moral emotions—loss, grief, remorse, shame, guilt—in surgical life, training, and practice.

#### **American Journal of Human Genetics**

Mar 06, 2025 Volume 112 Issue 3 p457-724

https://www.cell.com/ajhq/current

This month in The Journal

Alyson B. Barnes, Sara B. Cullinan

Publication of the 2023 NASEM report sparked discussions on the use of population descriptors in genetics and genomics research. Experts have offered guidance to researchers in various sub-fields, but little guidance has been provided for clinical laboratory settings. In this issue, Hatchell et al. build on their experience in clinical genomics laboratories to provide insight into the relevance of both conventional and ancestry-based population descriptors for genetic testing and reporting. There are advantages and disadvantages to the use of both types of descriptors.

#### **American Journal of Infection Control**

March 2025 Volume 53 Issue 3 p285-414 http://www.ajicjournal.org/current
Maior Articles

The impact of COVID-19 pandemic on reported notifiable infectious diseases in China: An interrupted time series analysis

Jin Li, et al.

Published online: October 22, 2024

p340-347

#### **American Journal of Preventive Medicine**

March 2025 Volume 68 Issue 3 p429-644 https://www.ajpmonline.org/current Research Articles

<u>Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate</u> Vaccine Compared With the Recommended Pneumococcal Vaccines in Older Adults

Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk, ... Lee H. Harrison, William Schaffner,

Richard K. Zimmerman

Published online: November 28, 2024 p518-526 Open Access

## **American Journal of Public Health**

March 2025 115(3)

http://ajph.aphapublications.org/toc/ajph/current

#### **EDITORIALS**

## **Vaccinating During Pregnancy: Are We Failing to Protect Our Mothers and Infants?**

Abbey B. Berenson MD, PhD 115(3), pp. 247–249

#### **Articles**

## <u>Impacts of State COVID-19 Vaccine Mandates for Health Care Workers on Health Sector Employment in the United States</u>

Yin Wang MA, Kevin Callison PhD, Julie H. Hernandez PhD and Charles Stoecker PhD

## <u>Uptake of Recommended Vaccines During Pregnancy Among Publicly and Privately Insured People in the United States, December 2020–September 2022</u>

Stacey L. Rowe PhD, MPH, BSc(Hons), Sheena G. Sullivan PhD, MPH, MSc, BSc(Hons), Flor M. Munoz MD, MSc, Matthew M. Coates MPH, Onyebuchi A. Arah MD, DSc, PhD, MPH, MSc and Annette K. Regan PhD, MPH

## <u>Parental Factors Associated With Measles–Mumps–Rubella Vaccination in US Children</u> <u>Younger Than 5 Years</u>

Eric Geng Zhou PhD, Jonathan Cantor PhD, Autumn Gertz MS, Brian Elbel PhD, MPH, John S. Brownstein PhD and Benjamin Rader PhD, MPH

## <u>Predictors of Persistent COVID-19 Vaccine Refusal Among Previously Infected Patients in Nebraska</u>

He (Julia) Bai MPH, David Brett-Major MD, MPH, Yi Du PhD, MS, Sai Paritala MPH, PharmD, Edward S. Peters DMD, DM, SCD, Kendra L. Ratnapradipa PhD, MSW and Patrick Maloney PhD, MPH

## **American Journal of Tropical Medicine and Hygiene**

Volume 112 (2025): Issue 2 (Feb 2025) <a href="https://www.ajtmh.org/view/journals/tpmd/112/2/tpmd.112.issue-2.xml">https://www.ajtmh.org/view/journals/tpmd/112/2/tpmd.112.issue-2.xml</a> [Reviewed earlier]

#### **Annals of Internal Medicine**

February 2025 Volume 178, Issue 2 <a href="https://www.acpjournals.org/toc/aim/current">https://www.acpjournals.org/toc/aim/current</a> [Reviewed earlier]

## Artificial Intelligence – An International Journal

Volume 339 February 2025 <a href="https://www.sciencedirect.com/journal/artificial-intelligence/vol/339/suppl/C">https://www.sciencedirect.com/journal/artificial-intelligence/vol/339/suppl/C</a> [Reviewed earlier]

#### **BMC Cost Effectiveness and Resource Allocation**

http://resource-allocation.biomedcentral.com/ (Accessed 08 Mar 2025) [No new digest content identified]

#### **BMC Health Services Research**

## http://www.biomedcentral.com/bmchealthservres/content

(Accessed 08 Mar 2025

## Hesitancy towards COVID-19 booster vaccine among healthcare workers in Bangladesh

Despite completing the COVID-19 vaccination series, healthcare workers (HCWs) remain at an elevated risk of re-infection. Booster uptake, though essential for this group, remains poorly characterized among Ban...

Authors: Homayra Rahman Shoshi, Ahamed Khairul Basher, Ashrak Shad Pyash, Md. Kamal Hossain,

Fahmida Chowdhury and Md Zakiul Hassan

Citation: BMC Health Services Research 2025 25:346 Content type: Research Published on: 6 March 2025

#### **BMC Infectious Diseases**

http://www.biomedcentral.com/bmcinfectdis/content (Accessed 08 Mar 2025) [No new digest content identified]

#### **BMC Medical Ethics**

http://www.biomedcentral.com/bmcmedethics/content (Accessed 08 Mar 2025) [No new digest content identified]

#### **BMC Medicine**

http://www.biomedcentral.com/bmcmed/content (Accessed 08 Mar 2025) [No new digest content identified]

#### **BMC Pregnancy and Childbirth**

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 08 Mar 2025) [No new digest content identified]

#### **BMC Public Health**

http://bmcpublichealth.biomedcentral.com/articles (Accessed 08 Mar 2025)

Prevalence and associated factors of immunization among under-five children in Somalia

Children worldwide can live lives free from various illnesses and disabilities due to vaccination. For instance, vaccination has eliminated smallpox, a deformative and frequently fatal illness that claimed an ...

Authors: Denekew Bitew Belay, Mahad Ibrahim Ali, Ding-Geng Chen and Umalkhair Abdi Jama

Citation: BMC Public Health 2025 25:924

Content type: Research Published on: 8 March 2025

## <u>Association of COVID-19 infection and COVID-19 vaccination with idiopathic sudden</u> sensorineural hearing loss in Malaysia: a case-control study

Previous studies indicated that the SARS-CoV-2 virus and COVID-19 vaccines may contribute to idiopathic sudden sensorineural hearing loss (ISSNHL). This nationwide study sought to evaluate the correlation betw...

Authors: Nur Sabrina Abdul Rahim, Xin-Jie Lim, E-Li Leong, Su-Yin Lim, Nur Azyani Amri, Chee Chean

Lim and Philip Rajan Devesahayam Citation: BMC Public Health 2025 25:920

Content type: Research Published on: 7 March 2025

#### **BMC Research Notes**

http://www.biomedcentral.com/bmcresnotes/content (Accessed 08 Mar 2025) [No new digest content identified]

#### **BMJ Evidence-Based Medicine**

February 2025 - Volume 30 - 1 https://ebm.bmj.com/content/30/1 [Reviewed earlier]

#### **BMJ Global Health**

February 2025 - Volume 10 - 2 https://gh.bmj.com/content/10/2 [Reviewed earlier]

## **Bulletin of the World Health Organization**

2025 Mar 1; 103(3)

https://www.who.int/publications/journals/bulletin/

**Articles** 

#### Birth-dose hepatitis B vaccine and bronchopulmonary dysplasia risks in preterm infants

Matthew F Daley, Jason M Glanz

Bull World Health Organ. 2025 Mar 1; 103(3): 178–178A. Published online 2025 Mar 1.

doi: 10.2471/BLT.24.293032 PMCID: PMC11865857

## Hepatitis B vaccination of preterm infants and risk of bronchopulmonary dysplasia: a cohort study, Australia

Hannah J Morgan, Marcel F Nold, Gonzalo Sepulveda Kattan, Diana Vlasenko, Atul Malhotra, James H Boyd, Hazel J Clothier, Jim P Buttery

Bull World Health Organ. 2025 Mar 1; 103(3): 187-193. Published online 2025 Jan 31.

doi: 10.2471/BLT.24.291683 PMCID: PMC11865856

#### The role of mortality surveillance in pandemic preparedness and response

Chalapati Rao, Don de Savigny, Emily Atuheire, Samantha Dolan, Daniel Cobos Munoz, Doris Ma Fat, Joy Ebonwu, Mona Sharan, Anthony Ofosu, Debbie Bradshaw, Rob Dorrington, Erin Nichols Bull World Health Organ. 2025 Mar 1; 103(3): 213–222. Published online 2025 Jan 27.

doi: 10.2471/BLT.24.292423

PMCID: PMC11865855

Proposal for a fourth indicator on vaccine uptake in the joint external evaluation tool

Lawrence R Stanberry, Tariro Makadzange, Wilmot G James, Janan J Dietrich, Peter J Hotez, Shabir A Madhi, Susan L Rosenthal, Martin Veller, Natalia Pasternak Taschner, James W Le Duc, Youngmee Jee, Anthony L Cunningham, Margie Danchin, Julie Leask

Bull World Health Organ. 2025 Mar 1; 103(3): 226-228. Published online 2025 Jan 20.

doi: 10.2471/BLT.24.292086

PMCID: PMC11865845

#### Cell

Mar 06, 2025 Volume 188 Issue 5 p1175-1456 https://www.cell.com/cell/current
[New issue; No digest content identified]

## **Child Care, Health and Development**

Volume 51, Issue 2 March 2025 <a href="https://onlinelibrary.wiley.com/toc/13652214/current">https://onlinelibrary.wiley.com/toc/13652214/current</a> [Reviewed earlier]

#### **Clinical Pharmacology & Therapeutics**

Volume 117, Issue 3 Pages: 599-857 March 2025 <a href="https://ascpt.onlinelibrary.wiley.com/toc/15326535/current">https://ascpt.onlinelibrary.wiley.com/toc/15326535/current</a> [Reviewed earlier]

## **Clinical Therapeutics**

March 2025 Volume 47 Issue 3 p179-248 http://www.clinicaltherapeutics.com/current [Reviewed earlier]

#### **Clinical Trials**

Volume 22 Issue 1, February 2025 <a href="https://journals.sagepub.com/toc/ctja/22/1">https://journals.sagepub.com/toc/ctja/22/1</a> [Reviewed earlier]

#### **Conflict and Health**

http://www.conflictandhealth.com/ [Accessed 08 Mar 2025]

Evaluation of contact tracing performance during an Ebola virus disease outbreak in a complex security environment: the case of North Kivu province, Democratic Republic of the Congo, 2018–2020

Authors: Willy Ngalamulume, Harry César Kayembe, Guy Mutombo, Mathias Mossoko, Annie Mutombo

and Didier Bompanque

Content type: Research 4 March 2025

## **Contemporary Clinical Trials**

Volume 150 March 2025

https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/150/suppl/C

[New issue; No digest content identified]

#### The CRISPR Journal

Volume 8, Issue 1 / February 2025 <a href="https://www.liebertpub.com/toc/crispr/8/1">https://www.liebertpub.com/toc/crispr/8/1</a> [Reviewed earlier]

## **Current Genetic Medicine Reports**

Volume 11, Issue 3-4 December 2023 <a href="https://link.springer.com/journal/40142/volumes-and-issues/11-3">https://link.springer.com/journal/40142/volumes-and-issues/11-3</a> [Reviewed earlier]

## **Current Medical Research and Opinion**

Volume 41, Issue 1 2025 <a href="https://www.tandfonline.com/toc/icmo20/current">https://www.tandfonline.com/toc/icmo20/current</a> [Reviewed earlier]

## **Current Opinion in Infectious Diseases**

February 2025 - Volume 38 - Issue 1 <a href="https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx">https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx</a> [Reviewed earlier]

#### **Current Protocols in Human Genetics**

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 08 Mar 2025] [No new digest content identified]

#### **Developing World Bioethics**

Volume 25, Issue 1 Pages: 1-79 March 2025 https://onlinelibrary.wiley.com/toc/14718847/current ORIGINAL ARTICLE Open Access

<u>The wisdom of claiming ownership of human genomic data: A cautionary tale for research institutions</u>

**Donrich Thaldar** 

Pages: 16-23 First Published: 31 January 2024

#### Open Access

<u>Understanding cultural values, norms and beliefs that may impact participation in genome-editing related research: Perspectives of local communities in Botswana</u>

Setlhomo Koloi-Keaikitse, Mary Kasule, Irene Kwape, Dudu Jankie, Dimpho Ralefala, Dolly

<u>Mogomotsi Ntseane</u>, <u>Gaonyadiwe George Mokone</u> Pages: 24-34 First Published: 11 January 2024

## **Development in Practice**

Volume 34, Issue 6, 2024 https://www.tandfonline.com/toc/cdip20/34/6 [Reviewed earlier]

## **Development Policy Review**

Volume 43, Issue 2 March 2025 <a href="https://onlinelibrary.wiley.com/toc/14677679/current">https://onlinelibrary.wiley.com/toc/14677679/current</a> [Reviewed earlier]

## **Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-

<u>issue</u>

[New issue; No digest content identified]

#### **Disasters**

Volume 49, Issue 1 January 2025 <a href="https://onlinelibrary.wiley.com/toc/14677717/2025/49/1">https://onlinelibrary.wiley.com/toc/14677717/2025/49/1</a> [Reviewed earlier]

#### **EMBO Reports**

Volume 26 Issue 3 10 February 2025 <a href="https://www.embopress.org/toc/14693178/current">https://www.embopress.org/toc/14693178/current</a> [Reviewed earlier]

## **Emerging Infectious Diseases**

Volume 31, Number 2—February 2025 <a href="http://wwwnc.cdc.gov/eid/">http://wwwnc.cdc.gov/eid/</a> [Reviewed earlier]

## **Epidemics**

Volume 49 December 2024 <a href="https://www.sciencedirect.com/journal/epidemics/vol/49/suppl/C">https://www.sciencedirect.com/journal/epidemics/vol/49/suppl/C</a> [Reviewed earlier]

## **Epidemiology and Infection**

Volume 153 - 2025 <a href="https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue">https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue</a> [Reviewed earlier]

#### **Ethics & Human Research**

Volume 47, Issue 1 Pages: 1-45 January–February 2025 <a href="https://onlinelibrary.wiley.com/toc/25782363/current">https://onlinelibrary.wiley.com/toc/25782363/current</a>

Moral distress in clinical research • Research with incarcerated and homeless women

## [Reviewed earlier]

### **Ethics & International Affairs**

Volume 38 - Issue 3 - Fall 2024 <a href="https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue">https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue</a> [Reviewed earlier]

#### **Ethics, Medicine and Public Health**

Volume 32 2024

https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc [Reviewed earlier]

## The European Journal of Public Health

Volume 35, Issue 1, February 2025 https://academic.oup.com/eurpub/issue/35/1 [Reviewed earlier]

## **Expert Review of Vaccines**

Volume 24, 2025 Issue 1 <a href="https://www.tandfonline.com/toc/ierv20/current">https://www.tandfonline.com/toc/ierv20/current</a> [Reviewed earlier]

### **Foreign Affairs**

January/February 2025 <a href="https://www.foreignaffairs.com/issues/2025/104/1">https://www.foreignaffairs.com/issues/2025/104/1</a> Special Section

Will Trump Change the World?

#### **Forum for Development Studies**

Volume 51, 2024 - Issue 3 <a href="http://www.tandfonline.com/toc/sfds20/current">http://www.tandfonline.com/toc/sfds20/current</a> [Reviewed earlier]

#### **Frontiers in Medicine**

https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237 [Accessed 08 Mar 2025] [No new digest content identified]

## **Gene Therapy - Nature**

Volume 32 Issue 1, January 2025 <a href="https://www.nature.com/gt/volumes/32/issues/1">https://www.nature.com/gt/volumes/32/issues/1</a> [Reviewed earlier]

#### **Genetics in Medicines**

Volume 27, Issue 3 March 2025

https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/3

[New issue; No digest content identified]

#### **Genome Medicine**

https://genomemedicine.biomedcentral.com/articles [Accessed 08 Mar 2025] [No new digest content identified]

#### **Global Health Action**

Volume 18, Issue 1 (2025) <a href="https://www.tandfonline.com/toc/zgha20/current?nav=tocList">https://www.tandfonline.com/toc/zgha20/current?nav=tocList</a> [Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 6 December 20, 2024 <a href="http://www.ghspjournal.org/content/current">http://www.ghspjournal.org/content/current</a> [Reviewed earlier]

## Global Legal Monitor & Legal Reports – Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/ https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\_desc [Accessed 08 Mar 2025] [No new digest content identified]

#### **Global Public Health**

Volume 20, Issue 1 (2025) <a href="http://www.tandfonline.com/toc/rgph20/current">http://www.tandfonline.com/toc/rgph20/current</a> [Reviewed earlier]

#### **Globalization and Health**

http://www.globalizationandhealth.com/ [Accessed 08 Mar 2025]

## <u>Corruption risks in COVID-19 vaccine deployment: lessons learned for future pandemic preparedness</u>

During the COVID-19 pandemic corruption risks were amplified in health systems globally, increasing health inequities within and between countries. During the pandemic, the deployment of COVID-19 vaccines, particularly concerning their procurement and distribution, had corruption risks given the large amounts of public and private funding allocated to them, the need for speed, the involvement of a high number of stakeholders, and often insufficient oversight. To explore this issue further, we conducted a descriptive, qualitative study of corruption risks in the COVID-19 vaccine deployment process.

Authors: Gul Saeed and Jillian Clare Kohler Citation: *Globalization and Health* 2025 21:8

Content type: Research Published on: 7 March 2025

## **Health and Human Rights**

Volume 26, Issue 2, December 2024 <a href="https://www.hhrjournal.org/volume-26-issue-2-december-2024/">https://www.hhrjournal.org/volume-26-issue-2-december-2024/</a> **Special Section: Distress Migration and the Right to Health**[Reviewed earlier]

## **Health Economics, Policy and Law**

Volume 19 - Issue 4 - October 2024 <a href="https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue">https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue</a> [Reviewed earlier]

## **Health Policy and Planning**

Volume 40, Issue 2, March 2025 https://academic.oup.com/heapol/issue/40/2 [Reviewed earlier]

## **Health Research Policy and Systems**

http://www.health-policy-systems.com/content [Accessed 08 Mar 2025] [No new digest content identified]

#### **Human Gene Therapy**

Volume 36, Issue 3-4 / February 2025 https://www.liebertpub.com/toc/hum/36/3-4 [Reviewed earlier]

#### **Humanitarian Practice Network**

https://odihpn.org/ Featured Publications [No new digest content identified]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 20 Issue 1, 2024 https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList Selected Content [Reviewed earlier]

## **Immunity**

Feb 11, 2025 Volume 58 Issue 2 p265-514 <a href="https://www.cell.com/immunity/current">https://www.cell.com/immunity/current</a> [Reviewed earlier]

## **Infectious Agents and Cancer**

http://www.infectagentscancer.com/ [Accessed 08 Mar 2025] [No new digest content identified]

## **Infectious Diseases of Poverty**

http://www.idpjournal.com/content [Accessed 08 Mar 2025] [No new digest content identified]

#### **International Health**

Volume 17, Issue 1, January 2025 <a href="https://academic.oup.com/inthealth/issue/17/1">https://academic.oup.com/inthealth/issue/17/1</a> [Reviewed earlier]

## **International Human Rights Law Review**

Volume 13 (2024): Issue 2 (Dec 2024) <a href="https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml">https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml</a> [Reviewed earlier]

## **International Journal of Community Medicine and Public Health**

Vol. 12 No. 2 (2025): February 2025 https://www.ijcmph.com/index.php/ijcmph/issue/view/121 [Reviewed earlier]

## **International Journal of Epidemiology**

Volume 54, Issue 1, February 2025 <a href="https://academic.oup.com/ije/issue/54/1">https://academic.oup.com/ije/issue/54/1</a> [New issue; No digest content identified]

## **International Journal of Human Rights in Healthcare**

Volume 17 Issue 4 2024 <a href="https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4">https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4</a> Table of contents [Reviewed earlier]

#### **JAMA**

March 4, 2025, Vol 333, No. 9, Pages 735-822 <a href="https://jamanetwork.com/journals/jama/currentissue">https://jamanetwork.com/journals/jama/currentissue</a> [New issue; No digest content identified]

#### **JAMA Health Forum**

February 2025, Vol 6, No. 2

https://jamanetwork.com/journals/jama-health-forum/issue [Reviewed earlier]

#### JAMA Pediatrics

February 2025, Vol 179, No. 2, Pages 111-224 <a href="https://jamanetwork.com/journals/jamapediatrics/currentissue">https://jamanetwork.com/journals/jamapediatrics/currentissue</a> [Reviewed earlier]

# **JBI Evidence Synthesis**

February 2025 - Volume 23 - Issue 2 <a href="https://journals.lww.com/jbisrir/Pages/currenttoc.aspx">https://journals.lww.com/jbisrir/Pages/currenttoc.aspx</a> [Reviewed earlier]

#### **Journal of Adolescent Health**

March 2025 Volume 76 Issue 3 p341-526 <a href="https://www.jahonline.org/current">https://www.jahonline.org/current</a> [Reviewed earlier]

# **Journal of Artificial Intelligence Research**

Vol. 82 (2025)

https://www.jair.org/index.php/jair

Contents

[New issue; No digest content identified]

## **Journal of Community Health**

Volume 50, Issue 1 February 2025 <a href="https://link.springer.com/journal/10900/volumes-and-issues/50-1">https://link.springer.com/journal/10900/volumes-and-issues/50-1</a> [Reviewed earlier]

## **Journal of Current Medical Research and Opinion**

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

https://www.cmro.in/index.php/jcmro/issue/view/91

[Reviewed earlier]

# **Journal of Development Economics**

Volume 173 March 2025

https://www.sciencedirect.com/journal/journal-of-development-economics/vol/173/suppl/C [Reviewed earlier]

# **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 4-5, October-December 2024

# http://journals.sagepub.com/toc/jre/current [Reviewed earlier]

# **Journal of Epidemiology & Community Health**

March 2025 - Volume 79 - 3 https://jech.bmj.com/content/79/3 [Reviewed earlier]

## **Journal of Evidence-Based Medicine**

Volume 18, Issue 1 March 2025 <a href="https://onlinelibrary.wiley.com/toc/17565391/current">https://onlinelibrary.wiley.com/toc/17565391/current</a> [Reviewed earlier]

#### **Journal of Global Ethics**

Volume 20, Issue 3 (2024)
<a href="http://www.tandfonline.com/toc/rjge20/current">http://www.tandfonline.com/toc/rjge20/current</a>
<a href="#">Special Issue: 20th Anniversary Forum</a>
<a href="#">[Reviewed earlier]</a>

# **Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 36, Number 1, February 2025 <a href="https://muse.jhu.edu/issue/54278">https://muse.jhu.edu/issue/54278</a> *Table of Contents*[Reviewed earlier]

## **Journal of Immigrant and Minority Health**

Volume 27, Issue 1 February 2025 <a href="https://link.springer.com/journal/10903/volumes-and-issues/27-1">https://link.springer.com/journal/10903/volumes-and-issues/27-1</a> [Reviewed earlier]

# **Journal of Immigrant & Refugee Studies**

Volume 23, Issue 1 (2025) <a href="https://www.tandfonline.com/toc/wimm20/current">https://www.tandfonline.com/toc/wimm20/current</a> [Reviewed earlier]

# **Journal of International Development**

Volume 37, Issue 1 Pages: 1-349 January 2025 <a href="https://onlinelibrary.wiley.com/toc/10991328/current">https://onlinelibrary.wiley.com/toc/10991328/current</a> [Reviewed earlier]

# **Journal of Medical Ethics**

February 2025 - Volume 51 - 2 http://jme.bmj.com/content/current [Reviewed earlier]

#### **Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 3 (2024) https://institutionalrepository.aah.org/jpcrr/ [Reviewed earlier]

#### The Journal of Pediatrics

Volume 277 February 2025 <a href="https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/277/suppl/C">https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/277/suppl/C</a> [Reviewed earlier]

# **Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024) <a href="https://www.tandfonline.com/toc/jppp20/17/1">https://www.tandfonline.com/toc/jppp20/17/1</a> [Reviewed earlier]

## **Journal of Public Health Management & Practice**

March/April 2025 - Volume 31 - Issue 2 https://journals.lww.com/jphmp/pages/currenttoc.aspx [New issue; No digest content identified]

# **Journal of Public Health Policy**

Volume 45, issue 4, December 2024 <a href="https://link.springer.com/journal/41271/volumes-and-issues/45-4">https://link.springer.com/journal/41271/volumes-and-issues/45-4</a> [Reviewed earlier]

## **Journal of the Royal Society – Interface**

March 2025 Volume 22 Issue 224 <a href="https://royalsocietypublishing.org/toc/rsif/current">https://royalsocietypublishing.org/toc/rsif/current</a> [New issue; No digest content identified]

#### **Journal of Travel Medicine**

Volume 32, Issue 1, January 2025 <a href="https://academic.oup.com/jtm/issue">https://academic.oup.com/jtm/issue</a> [Reviewed earlier]

# **Journal of Virology**

Volume 98 Number 12 December 2024 <a href="http://jvi.asm.org/content/current">http://jvi.asm.org/content/current</a> [Reviewed earlier]

#### The Lancet

Mar 01, 2025 Volume 405 Number 10480 p671-754

https://www.thelancet.com/journals/lancet/issue/current

Seminar

## **Tuberculosis**

Anete Trajman, Jonathon R Campbell, Tenzin Kunor, Rovina Ruslami, Farhana Amanullah, Marcel A Behr, Dick Menzies

Summary

Tuberculosis is a leading cause of death globally. Given the airborne transmission of tuberculosis, anybody can be infected, but people in high-incidence settings are more exposed. Risk of progression to disease is higher in the first years after infection, and in people with undernourishment, immunosuppression, or who smoke, drink alcohol, or have diabetes. Although cough, fever, and weight loss are hallmark symptoms, people with tuberculosis can be asymptomatic, so a high index of suspicion is required. Prompt diagnosis can be made by sputum examination (ideally with rapid molecular tests), but chest radiography can be helpful. Most people with disease can be treated with regimens of 6 months or less; longer regimens may be necessary for those with drug resistance. Central to successful treatment is comprehensive, person-centred care including addressing key determinants, such as undernourishment, smoking, and alcohol use, and optimising management of comorbidities, such as diabetes and HIV. Care should continue after treatment ends, as long-term sequelae are common. Prevention relies mostly on treatment with rifamycin-based regimens; current vaccines have limited efficacy. Ongoing research on shorter and safer regimens for infection and disease treatment, and simpler and more accurate diagnostic methods will be key for tuberculosis elimination.

# The Lancet Child & Adolescent Health

Mar 2025 Volume 9 Number 3 p151-210, e4-e9 https://www.thelancet.com/journals/lanchi/issue/current

Auticles

**Articles** 

<u>Early childhood developmental concerns following SARS-CoV-2 infection and COVID-19 vaccination during pregnancy: a Scottish population-level retrospective cohort study</u>
Iain Hardie, et al.

**Open Access** 

## **Viewpoint**

Ethical and legal considerations in the care of children and young people with high consequence infectious diseases (HCIDs): an approach to decision making Elizabeth Whittaker, et al.

Summary

High consequence infectious diseases (such as Ebola virus or avian influenza) require specialist management with strict isolation to avoid spread to health-care staff and the wider community. These infections present various ethical and legal issues for children and young people. Specific challenges include the impact of isolation on the child and family (potentially without a child's consent), limitations to care due to staff safety considerations, and reduction of resources for other children (due to potential closure of paediatric intensive care unit beds). The complex decision making required in these scenarios needs timely ethical support. As planning for future pandemics accelerates, we suggest that the ethical and legal considerations involved in delivering care to affected children and their families need urgent consideration, and we have highlighted the important areas for focus to provide a route map for this important undertaking.

# **Lancet Digital Health**

Mar 2025 Volume 7 Number 3 e167-e231 <a href="https://www.thelancet.com/journals/landig/issue/current">https://www.thelancet.com/journals/landig/issue/current</a>

[New issue; No digest content identified]

## **Lancet Global Health**

Mar 2025 Volume 13 Number 3 e372-e598

https://www.thelancet.com/journals/langlo/issue/current

Articles

<u>Prevalence of advanced HIV disease in sub-Saharan Africa: a multi-country analysis of nationally representative household surveys</u>

Dominik Stelzle, et al.

<u>Pregnant women as a sentinel population for genomic surveillance of malaria in the Democratic Republic of the Congo: a population-based study</u>

Marie Onyamboko, et al.

Health Policy

<u>Establishing the value of regional cooperation and a critical role for regional organisations in managing future health emergencies</u>

Afifah Rahman-Shepherd, et al.

#### **Lancet Infectious Diseases**

Mar 2025 Volume 25 Number 3 p243-356, e114-e190 https://www.thelancet.com/journals/laninf/issue/current Editorial

# **Should science be political?**

The Lancet Infectious Diseases

Series

The Modern Landscape of Ebola Disease

Ebola disease: bridging scientific discoveries and clinical application

Amanda Rojek, et al.

# **Lancet Public Health**

Mar 2025 Volume 10 Number 3 e165-e263 <a href="https://www.thelancet.com/journals/lanpub/issue/current">https://www.thelancet.com/journals/lanpub/issue/current</a> [New issue; No digest content identified]

# **Lancet Respiratory Medicine**

Mar 2025 Volume 13 Number 3 p189-288, e17-e19 <a href="https://www.thelancet.com/journals/lanres/issue/current">https://www.thelancet.com/journals/lanres/issue/current</a> [New issue; No digest content identified]

# **Maternal and Child Health Journal**

Volume 29, Issue 2 February 2025 <a href="https://link.springer.com/journal/10995/volumes-and-issues/29-2">https://link.springer.com/journal/10995/volumes-and-issues/29-2</a> [Reviewed earlier]

# **Medical Decision Making (MDM)**

Volume 45 Issue 2, February 2025 <a href="http://mdm.sagepub.com/content/current">http://mdm.sagepub.com/content/current</a> [Reviewed earlier]

## The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 102, Issue 4 Pages: 823-1031 December 2024 <a href="https://onlinelibrary.wiley.com/toc/14680009/current">https://onlinelibrary.wiley.com/toc/14680009/current</a> [Reviewed earlier]

## **Molecular Therapy**

Mar 05, 2025 Volume 33 Issue 3 p825-1304 <a href="https://www.cell.com/molecular-therapy/current">https://www.cell.com/molecular-therapy/current</a> [New issue; No digest content identified]

#### **Nature**

Volume 639 Issue 8053, 6 March 2025 https://www.nature.com/nature/volumes/638/issues/8052 Editorial 25 Feb 2025

## Trump 2.0: an assault on science anywhere is an assault on science everywhere

US President Donald Trump is taking a wrecking ball to science and to international institutions. The global research community must take a stand against these attacks.

#### **Nature Biotechnology**

Volume 43 Issue 2, February 2025 <a href="https://www.nature.com/nbt/volumes/43/issues/2">https://www.nature.com/nbt/volumes/43/issues/2</a> [Reviewed earlier]

## **Nature Communications**

https://www.nature.com/subjects/health-sciences/ncomms (Accessed08 Mar 2025) [Reviewed earlier]

#### **Nature Genetics**

Volume 57 Issue 2, February 2025 <a href="https://www.nature.com/ng/volumes/57/issues/2">https://www.nature.com/ng/volumes/57/issues/2</a> [Reviewed earlier]

# **Nature Human Behaviour**

Volume 9 Issue 2, February 2025 <a href="https://www.nature.com/nathumbehav/volumes/9/issues/2">https://www.nature.com/nathumbehav/volumes/9/issues/2</a> [New issue; No digest content identified]

#### **Nature Medicine**

Volume 31 Issue 2, February 2025 <a href="https://www.nature.com/nm/volumes/31/issues/2">https://www.nature.com/nm/volumes/31/issues/2</a> [Reviewed earlier]

# **Nature Reviews Drug Discovery**

Volume 24 Issue 2, February 2025 <a href="https://www.nature.com/nrd/volumes/24/issues/2">https://www.nature.com/nrd/volumes/24/issues/2</a> [Reviewed earlier]

## **Nature Reviews Genetics**

Volume 26 Issue 3, March 2025 https://www.nature.com/nrg/volumes/26/issues/3 Comment 06 Nov 2024

# **Exploring biodiversity through museomics**

In this Comment, the authors showcase how the emerging field of museomics — the application of multi-omic tools to natural history collections — is undergoing a rapid and exciting transformation, with new opportunities, challenges and confrontations with past legacies.

Charles C. Davis, Sandra Knapp

Review Article 20 Nov 2024

# Biobanking with genetics shapes precision medicine and global health

Biobanks help centralize specimen collections, store and disseminate data, and facilitate large-scale analyses. This Review discusses how biobanks facilitate genetics research towards advancing precision medicine and overviews potential solutions to their current limitations.

C. Scott Gallagher, Geoffrey S. Ginsburg, Anjené Musick

# **Nature Reviews Immunology**

Volume 25 Issue 3, March 2025 <a href="https://www.nature.com/nri/volumes/25/issues/3">https://www.nature.com/nri/volumes/25/issues/3</a> [New issue; No digest content identified]

## **New England Journal of Medicine**

Volume 392 No. 10 March 6, 2025 <a href="https://www.nejm.org/toc/nejm/medical-journal">https://www.nejm.org/toc/nejm/medical-journal</a> [New issue; No digest content identified]

#### **NEJM Evidence**

Volume 4 No. 2 February 2025

https://evidence.nejm.org/toc/evid/current

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

# njp Vaccines

https://www.nature.com/npjvaccines/

[Accessed 08 Mar 2025]
[No new digest content identified]

#### **Pediatrics**

Volume 155, Issue 3 March 2025 https://publications.aap.org/pediatrics/issue/155/3 [New issue; No digest content identified]

#### **PharmacoEconomics**

Volume 43, Issue 3 March 2025 <a href="https://link.springer.com/journal/40273/volumes-and-issues/43-3">https://link.springer.com/journal/40273/volumes-and-issues/43-3</a> [Reviewed earlier]

# **PLoS Biology**

https://journals.plos.org/plosbiology/ (Accessed 08 Mar 2025) [No new digest content identified]

#### **PLoS Genetics**

https://journals.plos.org/plosgenetics/ (Accessed 08 Mar 2025) [No new digest content identified]

#### **PLoS Global Public Health**

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\_NEWEST\_FIRST&filterStartDate=2 021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 08 Mar 2025)

<u>High confidence and demand for hepatitis E vaccine during an outbreak in Bentiu, South</u> Sudan: A qualitative study

Aybüke Koyuncu, Kinya Vincent Asilaza, John Rumunu, Joseph Wamala, Priscillah Gitahi, Zelie Antier, Jetske Duncker, Patrick Nkemenang, Primitive Gakima, Melat Haile, Etienne Gignoux, Manuel Albela, Frederick Beden Loro, Duol Biem, Monica Rull, Andrew S. Azman, Iza Ciglenecki, Robin Nesbitt Research Article | published 06 Mar 2025 PLOS Global Public Health https://doi.org/10.1371/journal.pgph.0003482

## **PLoS Medicine**

https://journals.plos.org/plosmedicine/ (Accessed 08 Mar 2025) [No new digest content identified]

# **PLoS Neglected Tropical Diseases**

http://www.plosntds.org/
(Accessed 08 Mar 2025)
[No new digest content identified]

#### **PLoS One**

http://www.plosone.org/ [Accessed 08 Mar 2025] [No new digest content identified]

# **PLoS Pathogens**

http://journals.plos.org/plospathoge ns/ [Accessed 08 Mar 2025] [No new digest content identified]

# PNAS - Proceedings of the National Academy of Sciences of the United States

March 11, 2025 | vol. 122 | no. 10 https://www.pnas.org/toc/pnas/122/10 [New issue; No digest content identified]

## **PNAS Nexus**

Volume 4, Issue 2, February 2025 https://academic.oup.com/pnasnexus/issue/4/2 [New issue; No digest content identified]

# **Prehospital & Disaster Medicine**

Volume 39 - Issue 6 - December 2024 <a href="https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue">https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue</a> [Reviewed earlier]

#### **Preventive Medicine**

Volume 191 February 2025 <a href="https://www.sciencedirect.com/journal/preventive-medicine/vol/191/suppl/C">https://www.sciencedirect.com/journal/preventive-medicine/vol/191/suppl/C</a> [Reviewed earlier]

# **Proceedings of the Royal Society B**

March 2025 Volume 292 Issue 2042 <a href="https://royalsocietypublishing.org/toc/rspb/current">https://royalsocietypublishing.org/toc/rspb/current</a> [New issue; No digest content identified]

#### **Public Health**

Volume 240 Pages 1-222 (March 2025)
<a href="https://www.sciencedirect.com/journal/public-health/vol/240/suppl/C">https://www.sciencedirect.com/journal/public-health/vol/240/suppl/C</a>
Research article Abstract only

Appraisal of World Health Organization guidelines for priority infectious diseases with potential to cause public health emergencies

Amin Sharifan, Hebatullah Abdulazeem, Rehab Meckawy, Martial Sonkoue Pianta, ... Tiffany Gust Duque

Pages 112-118

#### **Public Health Ethics**

Volume 17, Issue 3, November 2024 <a href="http://phe.oxfordjournals.org/content/current">http://phe.oxfordjournals.org/content/current</a> [Reviewed earlier]

## **Public Health Genomics**

2025, Vol. 28, No. 1 https://karger.com/phg/issue/28/1 [Reviewed earlier]

# **Public Health Reports**

Volume 140 Issue 1, January/February 2025 <a href="https://journals.sagepub.com/toc/phrg/140/1">https://journals.sagepub.com/toc/phrg/140/1</a> [Reviewed earlier]

## **Qualitative Health Research**

Volume 35 Issue 2, February 2025 <a href="https://journals.sagepub.com/toc/QHR/current">https://journals.sagepub.com/toc/QHR/current</a> [Reviewed earlier]

#### **Research Ethics**

Volume 21 Issue 1, January 2025 http://journals.sagepub.com/toc/reab/current [Reviewed earlier]

## **Reproductive Health**

http://www.reproductive-health-journal.com/content [Accessed 08 Mar 2025] [No new digest content identified]

# Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles [No new digest content identified]

## **Risk Analysis**

Volume 45, Issue 2 pages: 265-472 February 2025 <a href="https://onlinelibrary.wiley.com/toc/15396924/current">https://onlinelibrary.wiley.com/toc/15396924/current</a> [Reviewed earlier]

# **Risk Management and Healthcare Policy**

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56

[Accessed 08 Mar 2025]

[No new digest content identified]

## **Royal Society Open Science**

March 2025 Volume 12 Issue 3

https://royalsocietypublishing.org/toc/rsos/current

Review articles

# The academic impact of Open Science: a scoping review

Thomas Klebel, et al.

Published:05 March 2025Article ID:241248

#### Science

Volume 387| Issue 6738| 7 Mar 2025

https://www.science.org/toc/science/current

Policy Forum

# Global withdrawal of Sabin oral poliovirus type 2 vaccine in 2016

Evaluation guides strategy for the polio eradication endgame

BY Natalia A. Molodecky, Roland W. Sutter

06 Mar 2025: 1042-1044 FULL ACCESS

[Excerpt]

Live Sabin oral poliovirus vaccine (OPV), a live-attenuated vaccine, is genetically unstable and can revert back to neurovirulence and transmissibility, causing vaccine-associated paralytic poliomyelitis (VAPP) and circulating vaccine-derived poliovirus (cVDPV). Following a resolution of the World Health Assembly (WHA) in 2015, the Global Polio Eradication Initiative (GPEI) set the target for global withdrawal of the type 2 component of OPV (OPV2) for April 2016 (i.e., the switch). Within 12 to 18 months after the switch, it became apparent that the GPEI struggled to close out (stop and confirm absence of transmission) cVDPV2 outbreaks from undetected transmission and new emergences from OPV2 use in outbreak control. In 2023, the GPEI began discussing the global cessation of all Sabin polioviruses, necessitating the discontinuation of bivalent (type 1 and 3) OPV (i.e., bOPV). We attempt to identify and highlight the causes for the post-switch epidemiologic situation and offer some suggestions on how to avert such a development in the future...

#### Letters

# **Prepare now for a potential H5N1 pandemic**

BY Jesse L. Goodman, Norman W. Baylor, Rebecca Katz, Lawrence O. Gostin, Rick A. Bright, Nicole Lurie, Bruce G. Gellin
06 Mar 2025

# **Science and Engineering Ethics**

Volume 31, Issue 1 February 2025 <a href="https://link.springer.com/journal/11948/volumes-and-issues/31-1">https://link.springer.com/journal/11948/volumes-and-issues/31-1</a> [Reviewed earlier]

## **Science Translational Medicine**

Volume 17| Issue 788| 5 Mar 2025 https://www.science.org/toc/stm/current Research Articles

# An oral norovirus vaccine tablet was safe and elicited mucosal immunity in older adults in a phase 1b clinical trial

BY Becca A. Flitter, et al.

05 Mar 2025

An oral norovirus vaccine tablet is safe and induces strong mucosal and systemic immune responses in adults aged 55 to 80 years.

Editor's summary

Although most humans infected with norovirus recover after an unpleasant few days, susceptible populations, including older adults, can develop severe disease. A vaccine, especially one that is easy to administer, would thus be an important advance for protecting older adult populations. Here, Flitter et al. report that an orally delivered vaccine against the norovirus GI.1 variant is safe and elicits robust immune responses in adults between 55 and 80 years old. This included elicitation of antibody responses in the saliva and nasal cavity, potentially offering a first line of defense against mucosal pathogens such as norovirus. These promising clinical trial results support further development of oral norovirus vaccines, including ongoing studies with bivalent vaccines. —Courtney Malo

# **Scientific Reports**

https://www.nature.com/srep/articles?type=article [Accessed 08 Mar 2025] [No new digest content identified]

#### **Social Science & Medicine**

Volume 365 January 2025 <a href="https://www.sciencedirect.com/journal/social-science-and-medicine/vol/365/suppl/C">https://www.sciencedirect.com/journal/social-science-and-medicine/vol/365/suppl/C</a> [Reviewed earlier]

## **Systematic Reviews**

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 08 Mar 2025] [No new digest content identified]

#### **Theoretical Medicine and Bioethics**

Volume 46, Issue 1 February 2025

https://link.springer.com/journal/11017/volumes-and-issues/46-1

# Special Issue on Bioethics and Language

Issue Editor: Matthew Vest

[New issue; No digest content identified]

#### **Travel Medicine and Infectious Diseases**

Volume 63 January—February 2025 <a href="https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/63/suppl/C">https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/63/suppl/C</a> [Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 30, Issue 3 Pages: i-iv, 143-230 March 2025 <a href="https://onlinelibrary.wiley.com/toc/13653156/current">https://onlinelibrary.wiley.com/toc/13653156/current</a>

[New issue; No digest content identified]

#### Vaccine

Volume 50 19 March 2025

https://www.sciencedirect.com/journal/vaccine/vol/50/suppl/C

Review article Open access

<u>Advancing local manufacturing capacities for vaccines within Africa – Opportunities, priorities and challenges</u>

Joachim Doua, Nicaise Ndembi, Jochen Auerbach, Jean Kaseya, Alimuddin Zumla Article 126829

**Abstract** 

Our viewpoint focuses on the paradox that Africa represents 25 % of total global vaccine usage, yet 99 % of these vaccines are manufactured overseas. In view of the iniquitous supply and distribution of COVID-19 vaccines to Africa during the pandemic, we emphasize the need for scaling up local vaccine manufacturing capacities across Africa. We review current vaccine manufacturing capacities within Africa, highlight priority vaccines needs, and describe opportunities and challenges of advancing local manufacturing capacities within Africa. Of 11 manufacturers in Africa, ten have operational formulation/fill/finish capacities. However, capacities to produce active vaccine components locally are very limited and leveraging of vaccine technology platforms such as live-attenuated virus, inactivated virus, and mRNA remain scanty. South Africa and Senegal are the only countries with end-to-end manufacturing capacities. Based on market demand, manufacturing complexity, target population, disease burden and vaccination regimen, the top 5 priority vaccines identified for local manufacturing in Africa were measles-rubella, yellow fever, cholera, rotavirus, and meningococcal vaccines. Enablers identified for Africa's vaccine manufacturing initiatives include: a preferential procurement of Africanmade vaccines for sustainable and reliable volumes through GAVI and UNICEF; deal preparation to target investments avoiding overproduction; technology transfers; regulatory systems strengthening; R&D capacities and infrastructure. Thus, African vaccine manufacturers and all stakeholders should focus taking forward the portfolio of activities required for continental vaccine manufacturing, including regulatory strengthening capacities, training and workforce development, rather than only focus on efforts that benefit a particular manufacturer or country. Optimism for advancing vaccine manufacturing in Africa comes from the announcement in December 2023 by GAVI for the establishment of the African Vaccine Manufacturing Accelerator, a financing mechanism of USD 1 billion aimed at creating a sustainable vaccine manufacturing industry in Africa. However, many challenges need to be overcome including that of having secure funding for sustaining what is developed.

## Review article Open access

Realist review of low- to upper-middle-income country experiences on integration of HPV vaccination with other adolescent health services

Mary Carol Jennings, Sarah Nabia, Christopher Morgan, Chinelo Cynthia Nduka, ... Chizoba Wonodi Article 126833

Research article Open access

Attitudes and beliefs about vaccination among adults in the United States: A real-world, cross-sectional, web-based survey study

Amanda L. Eiden, deMauri S. Mackie, Kushal Modi, Sheila Drakeley, ... Anthony DiFranzo Article 126807

Research article Abstract only

Health system barriers to HPV-vaccination in adolescent females with a Moroccan or Turkish migration background in the Netherlands: A qualitative study

Bert J.D. van Enter, Janine de Zeeuw, Okan Bakar, Siham Bakhlakh, ... Danielle E.M.C. Jansen

Research article Abstract only

# <u>Costing approaches for vaccine-preventable disease surveillance: Lessons from Ethiopia and Nepal</u>

Roopa Darwar, Xiaoxian Huang, Aschalew Abayeneh, Senait Alemayehu Beshah, ... Nelly Mejia Article 126776

#### **Vaccines**

https://www.mdpi.com/journal/vaccines [Accessed 08 Mar 2025] [No new digest content identified]

## Value in Health

February 2025 Volume 28 Issue 2 p175-322 <a href="https://www.valueinhealthjournal.com/current">https://www.valueinhealthjournal.com/current</a> [Reviewed earlier]

# **World Development**

Volume 187 March 2025 <a href="https://www.sciencedirect.com/journal/world-development/vol/187/suppl/C">https://www.sciencedirect.com/journal/world-development/vol/187/suppl/C</a> [Reviewed earlier]

::::::

# Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

# **Pre-Print Servers**

## arxiv

https://arxiv.org/

[Accessed 08 Mar 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2503.04572 (cross-list from physics.soc-ph) [pdf, html, other]

Social Imitation Dynamics of Vaccination Driven by Vaccine Effectiveness and Beliefs
Feng Fu, Ran Zhuo, Xingru Chen

arXiv:2503.04527 (cross-list from math.DS) [pdf, html, other]

# The nexus between disease surveillance, adaptive human behavior and epidemic containment

Baltazar Espinoza, Roger Sanchez, Jimmy Calvo-Monge, Fabio Sanchez

arXiv:2503.02167 (cross-list from cs.ET) [pdf, html, other]

<u>Leveraging Large Language Models for Enhanced Digital Twin Modeling: Trends, Methods,</u> and Challenges

Linyao Yang, Shi Luo, Xi Cheng, Lei Yu

## **Gates Open Research**

https://gatesopenresearch.org/browse/articles [Accessed 08 Mar 2025] [No new digest content identified]

#### medRxiv

https://www.medrxiv.org/content/about-medrxiv [Accessed 08 Mar 2025]

[Filter: All articles]

[Website not responding at inquiry]

# **OSF Pre-prints**

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]
[No new digest content identified]

## **Wellcome Open Research**

https://wellcomeopenresearch.org/browse/articles

[Accessed 08 Mar 2025] Open Letter Open Access

<u>Transforming evidence-informed vaccine decision-making across Africa: Insights from three years of the annual vaccinology course for national immunisation technical advisory groups (AVCN)</u>

[version 1; peer review: awaiting peer review]

Edina Amponsah-Dacosta, et al.

**Abstract** 

Background

National Immunisation Technical Advisory Groups (NITAGs) play a critical role in evidence-informed decision-making (EIDM) for immunisation programs. However, African NITAGs face challenges, including limited technical capacity, inadequate resources, and insufficient vaccinology training tailored to their needs. To address these gaps, the NITAG Support Hub (NISH) launched the Annual Vaccinology Course for NITAGs (AVCN) in 2022.

Methods

The AVCN is a five-day residential course designed to enhance the technical and operational capacity of NITAGs. It combines didactic lectures, interactive sessions, and case studies to provide practical knowledge in vaccinology, health economics, and EIDM. Participants are selected in collaboration with the World Health Organisation (WHO), ensuring representation from diverse linguistic and geographic regions.

Study Protocol Open Access

REVISED - Infrastructure, capabilities, and capacities required for clinical trials design and delivery: A rapid scoping review of recommendations and regulations

[version 2; peer review: 1 approved, 1 approved with reservations] Laura Merson, et al.

Plain language summary

Clinical trials are essential for improving healthcare, but for them to be effective, they need to be high quality. Poor quality trials waste resources and harm public trust in science. During the COVID-19 pandemic, many clinical trials suffered from issues like being underpowered and of low quality. Additionally, clinical trials were underrepresented in low- and middle-income countries (LMICs), with few being led by researchers from those regions.

To address these issues, the World Health Assembly (WHA) and other global bodies have called for stronger global clinical trial infrastructure. The WHA 75.8 resolution, for example, encourages organizations to support high-quality trials, especially in developing countries. Understanding the infrastructure, capabilities, and resources required for running effective trials is essential for improving clinical research globally. This knowledge can help countries and institutions identify gaps and areas for improvement.

Clinical Trials Units (CTUs) are specialized teams or facilities responsible for managing various aspects of clinical trials. These units ensure regulatory compliance, participant recruitment, data management, and trial oversight. CTUs can differ based on the type of clinical trials they handle. For example, different resources are needed for phase I trials, multi-site trials, and trials involving participant recruitment.

There is no globally accepted framework for assessing CTUs. To fill this gap, this review seeks to develop a "CTU Maturity Framework" to evaluate national and institutional resources and provide guidance on strengthening clinical trial operations. A rapid scoping review of literature will inform this framework, allowing for the identification of best practices, regulatory benchmarks, and guidance for clinical trial units worldwide.

This framework aims to improve clinical trials across countries, supporting better health outcomes through high-quality research.

\* \* \*

# Think Tanks

**Brookings** [to 08 Mar 2025] http://www.brookings.edu/ Reports, Events Research

**Health and AI: Advancing responsible and ethical AI for all communities** 

Nicol Turner Lee, Malaika Simmons, and Michael Crawford March 3, 2025

- :: Artificial intelligence has begun to revolutionize health care by improving efficiency, accuracy, accessibility, and outcomes. Its use also poses risks, such as algorithmic bias and data privacy concerns.
- :: Ensuring AI is safe and effective requires designing, deploying, and using these technologies to benefit intended communities, in collaboration with partners and developers who understand the nuances of those impacted by AI or have relevant lived experiences.
- :: Collaboration between governments, companies, and the health care industry can help form AI governance structures that prioritize equitable health outcomes and ensure emerging technologies will benefit all communities..

# **Center for Global Development** [to 08 Mar 2025]

https://www.cgd ev.org/ All Research CGD NOTES

# The Future of US Foreign Assistance: How Low Can They Go?

Karen Mathiasen and Nico Martinez

March 06, 2025

The dramatic and unexpected cessation of US foreign aid could change the trajectory of development assistance for years to come. The sudden stop in funding is reverberating globally, destabilizing the aid community and cutting off access to hundreds of lifesaving programs affecting millions of peopl...

## **Chatham House** [to 08 Mar 2025]

https://www.chathamhouse.org/ Selected Analysis, Comment, Events No new digest content identified.

# **Council on Foreign Relations** [to 08 Mar 2025]

https://www.cfr.org/media/news-releases New Releases [Selected] No new digest content identified.

CSIS [to 08 Mar 2025]
https://www.csis.org/
Reports [Selected]
No new digest content identified.

# **Kaiser Family Foundation** [to 08 Mar 2025]

https://www.kff.org/search/?post\_type=press-release

Newsroom

<u>Poll: Two Thirds Believe Dissolving USAID Will Lead to More Illness and Death Globally,</u>
<u>While Nearly Half Say It Would Significantly Reduce the Budget Deficit and Fund Domestic</u>
<u>Programs</u>

March 4, 2025 News Release

As the Trump administration works to dissolve the U.S. Agency for International Development (USAID), a new KFF poll finds that two-thirds (67%) of the public believe these actions will increase illness and death in low-income countries, and a similar majority (62%) believe it will result in more humanitarian crises around...

# McKinsey Global Institute [to 08 Mar 2025]

https://www.mckinsey.com/mgi/overview

Latest Research

No new digest content identified.

## **ODI [Overseas Development Institute]** [to 08 Mar 2025]

https://odi.org/en/publications/

Publications [Selected]
No new digest content identified.

# **Pew Research Center** [to 08 Mar 2025]

https://www.pewresearch.org/ Latest Publications [Selected] No new digest content identified.

**Rand** [to 08 Mar 2025]

https://www.rand.org/pubs.html Published Research [Selected] Commentary Mar 5, 2025

# **Combating America's Chronic Disease Epidemic**

Effectively combating the chronic disease epidemic in the United States necessitates prioritization and significant investment in addressing all the contributing factors—including lifestyle and environmental factors, low health literacy, ineffective approaches to preventative care, and poor health care access.

Urban Institute [to 08 Mar 2025] https://www.urban.org/publications New Research Publications - Selected

Research Report

Reducing Federal Support for Medicaid Expansion Would Shift Costs to States and Likely Result in Coverage Losses

February 24, 2025

**World Economic Forum** [to 08 Mar 2025]

https://agenda.weforum.org/press/ Media [Selected] No new digest content identified.

## Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

::::::

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates Medical Research Institute</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.